Profile data is unavailable for this security.
About the company
3D Medicines Inc is a holding company mainly engaged in the research and development (R&D) and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The Company has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The Company's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The Company also has a number of innovative drug research and development pipelines. The Company primarily operates in the domestic Chinese market.
- Revenue in HKD (TTM)539.11m
- Net income in HKD-495.99m
- Incorporated2018
- Employees198.00
- Location3D Medicines IncSHANGHAI ChinaCHN
- Websitehttps://www.3d-medicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hin Sang Group (Interntnl) Hldng Co Ltd | 92.62m | -36.71m | 316.62m | 247.00 | -- | 1.52 | -- | 3.42 | -0.0336 | -0.0336 | 0.0848 | 0.1913 | 0.1536 | 2.34 | 10.34 | 374,967.60 | -6.04 | -5.11 | -9.78 | -7.04 | 61.98 | 59.72 | -39.30 | -28.42 | 0.1287 | -1.68 | 0.6054 | -- | 13.70 | -12.83 | 25.84 | -- | -69.21 | -- |
| Transcenta Holding Ltd | 24.63m | -395.54m | 452.80m | 200.00 | -- | 0.4229 | -- | 18.39 | -0.974 | -0.974 | 0.0607 | 2.46 | 0.0131 | 0.8106 | 0.5768 | 114,540.40 | -21.08 | -- | -29.77 | -- | 26.02 | -- | -1,606.19 | -- | 1.04 | -31.65 | 0.2826 | -- | -47.15 | -- | -13.72 | -- | -- | -- |
| Uni-Bio Science Group Ltd | 508.40m | 98.86m | 474.60m | 458.00 | 4.85 | 1.50 | 3.99 | 0.9335 | 0.0159 | 0.0159 | 0.0812 | 0.0514 | 1.27 | 2.23 | 9.05 | 1,249,140.00 | 24.76 | 1.46 | 32.97 | 1.97 | 83.51 | 80.59 | 19.44 | 1.23 | 2.17 | 168.55 | 0.2267 | 0.00 | 10.08 | 29.08 | 84.04 | -- | 84.98 | -- |
| Tianda Pharmaceuticals Ltd | 384.68m | -47.26m | 509.56m | 695.00 | -- | 0.9358 | -- | 1.32 | -0.022 | -0.022 | 0.1789 | 0.2533 | 0.4341 | 2.97 | 4.46 | 445,745.10 | -5.34 | -- | -7.97 | -- | 45.83 | -- | -12.30 | -- | 0.6748 | -9.51 | 0.1536 | -- | -- | -- | -- | -- | -- | -- |
| 3D Medicines Inc | 539.11m | -495.99m | 557.73m | 198.00 | -- | 0.5964 | -- | 1.03 | -2.11 | -2.11 | 2.26 | 3.62 | 0.3746 | 4.94 | 5.79 | 2,722,764.00 | -37.27 | -- | -50.88 | -- | 91.97 | -- | -99.50 | -- | 2.56 | -- | 0.2517 | -- | 11.91 | -- | 48.78 | -- | -- | -- |
| Lee's Pharmaceutical Holdings Ltd | 1.20bn | 63.06m | 694.83m | 1.06k | 11.02 | 0.4055 | 3.54 | 0.5795 | 0.1071 | 0.1071 | 2.04 | 2.91 | 0.4403 | 2.11 | 9.70 | 1,134,410.00 | 1.98 | 13.33 | 2.52 | 17.76 | 51.49 | 61.92 | 4.50 | 36.20 | 0.7425 | 6.12 | 0.132 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
| Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 925.32m | 189.30m | 733.93m | 678.00 | 3.88 | 0.4199 | 5.78 | 0.7932 | 0.3379 | 0.3379 | 1.65 | 3.12 | 0.3574 | 2.10 | 2.94 | 1,091,177.00 | 7.31 | 7.67 | 10.25 | 10.48 | 75.46 | 78.79 | 20.46 | 20.68 | 1.62 | -- | 0.0502 | 7.22 | -0.0049 | 5.38 | -23.43 | -1.67 | -1.14 | -- |
| Zhaoke Ophthalmology Ltd | 63.10m | -250.42m | 748.21m | 297.00 | -- | 0.3337 | -- | 11.86 | -0.4597 | -0.4597 | 0.1158 | 4.11 | 0.0233 | 1.25 | 0.8868 | 201,601.40 | -9.23 | -- | -10.51 | -- | 82.03 | -- | -396.86 | -- | 5.48 | -24.02 | 0.1114 | -- | -- | -- | 5.47 | -- | -- | -- |
| Fusen Pharmaceutical Co Ltd | 469.27m | -98.90m | 749.96m | 1.14k | -- | 1.31 | -- | 1.60 | -0.1326 | -0.1326 | 0.6299 | 0.7654 | 0.3212 | 1.68 | 3.35 | 408,769.60 | -6.77 | 0.9678 | -13.96 | 1.74 | 53.18 | 51.95 | -21.08 | 2.59 | 0.526 | -2.27 | 0.4031 | 27.95 | 15.02 | 4.13 | -4.83 | -- | 0.2124 | -- |
| Jbm (Healthcare) Ltd | 648.42m | 130.46m | 756.24m | 279.00 | 6.22 | 0.7879 | 4.12 | 1.17 | 0.1479 | 0.1479 | 0.7338 | 1.17 | 0.4645 | 4.25 | 5.98 | 2,324,068.00 | 9.83 | 4.38 | 12.04 | 5.52 | 52.14 | 46.47 | 21.16 | 12.69 | 1.25 | 89.68 | 0.1155 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Pak Fah Yeow International Ltd | 265.21m | 96.45m | 804.03m | 101.00 | 8.34 | 1.07 | 7.75 | 3.03 | 0.3094 | 0.3094 | 0.8507 | 2.41 | 0.2869 | 2.84 | 23.53 | 2,600,118.00 | 10.44 | 3.99 | 11.32 | 4.18 | 87.05 | 80.79 | 36.37 | 21.27 | 4.22 | 5.26 | 0.0055 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
| Zhongzhi Pharmaceutical Holdings Ltd | 2.25bn | 122.77m | 820.42m | 2.74k | 6.55 | 0.6722 | 3.90 | 0.364 | 0.145 | 0.145 | 2.66 | 1.41 | 1.09 | 2.68 | 6.10 | 852,889.20 | 5.99 | 7.69 | 9.17 | 11.75 | 57.55 | 60.44 | 5.49 | 6.73 | 0.9033 | 43.87 | 0.1516 | 42.46 | 12.26 | 12.41 | 53.00 | 13.86 | 17.65 | 3.22 |
Data as of Sep 20 2024. Currency figures normalised to 3D Medicines Inc's reporting currency: Hong Kong Dollar HKD
2.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.49m | 0.96% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 2.04m | 0.79% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 703.50k | 0.27% |
| E Fund Asset Management Co. Ltd.as of 30 Jun 2024 | 417.50k | 0.16% |
| China Asset Management (Hong Kong) Ltd.as of 28 Jun 2024 | 197.42k | 0.08% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 164.50k | 0.06% |
| Dimensional Fund Advisors LPas of 31 May 2024 | 111.00k | 0.04% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 85.00k | 0.03% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 72.00k | 0.03% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 61.00k | 0.02% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
